Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.40 |
| ▸ | BCHE | P06276 | 8/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543731 | 0.93 | USP2 (0.39) | PIK3CALMNASMN1; SMN2 | |
| SCHEMBL2548141 | 0.92 | ACHE (0.43) | ACHEP2RX7BCHEDRD2DRD3 | |
| SCHEMBL2541760 | 0.88 | ACHE (0.42) | ACHEP2RX7BCHEDRD2DRD3 | |
| SCHEMBL2541718 | 0.86 | ACHE (0.37) | ACHEP2RX7BCHEDRD2DRD3 | |
| SCHEMBL2540214 | 0.86 | USP2 (0.40) | PIK3CALMNASMN1; SMN2 | |
| SCHEMBL2541335 | 0.85 | RAB9A (0.38) | ACHEP2RX7BCHEGRIN2BLMNA | |
| SCHEMBL2541766 | 0.85 | LMNA (0.36) | ACHEP2RX7BCHEGRIN2BCYP3A4 | |
| SCHEMBL2544861 | 0.84 | ACHE (0.36) | ACHEP2RX7BCHEDRD2DRD3 | |
| SCHEMBL2546284 | 0.83 | ALDH1A1 (0.42) | LMNASMN1; SMN2 | |
| SCHEMBL2543264 | 0.83 | USP2 (0.40) | ACHEGRIN2BLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | TPMT, MET, PAICS | ACHE 2277/4885P2RX7 116/4885BCHE 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.